NO20072983L - Anvendelse av paratyroidhormon for fremstilling av et medikament for a redusere risiko for frakturer - Google Patents

Anvendelse av paratyroidhormon for fremstilling av et medikament for a redusere risiko for frakturer

Info

Publication number
NO20072983L
NO20072983L NO20072983A NO20072983A NO20072983L NO 20072983 L NO20072983 L NO 20072983L NO 20072983 A NO20072983 A NO 20072983A NO 20072983 A NO20072983 A NO 20072983A NO 20072983 L NO20072983 L NO 20072983L
Authority
NO
Norway
Prior art keywords
reduce
risk
manufacture
parathyroid hormone
drug
Prior art date
Application number
NO20072983A
Other languages
English (en)
Inventor
Janet Mary Hock
Gregory A Gaich
Willard H Dere
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072983(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20072983L publication Critical patent/NO20072983L/no
Application filed by Lilly Co Eli filed Critical Lilly Co Eli

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Oppfinnelsen angår anvendelse av paratyroidhormon for fremstilling av et medikament for å redusere risiko for flukturer. Medikamentet oppnådd ved anvendelse av oppflnnelsen kan anvendes for å øke hardheten eller stivheten til ben ved et sete med et potensielt eller virkelig traume, slik som hoften eller ryggraden til en person med risiko for eller som lider av osteoporose. Anvendelsen ifølge oppflnnelsen kan redusere sannsynligheten for vertebralfluktur, redusere tilfellet av multiple vertebrale fluktur, redusere alvorligheten av vertebra! fliaktur og/eller redusere forekomst av ikke-vertebral fraktur.
NO20072983A 1998-08-19 2007-06-11 Anvendelse av paratyroidhormon for fremstilling av et medikament for a redusere risiko for frakturer NO20072983L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US9974698P 1998-09-10 1998-09-10
PCT/US1999/018961 WO2000010596A1 (en) 1998-08-19 1999-08-19 Method of increasing bone toughness and stiffness and reducing fractures

Publications (1)

Publication Number Publication Date
NO20072983L true NO20072983L (no) 2000-11-24

Family

ID=26792729

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20005947A NO323984B1 (no) 1998-08-19 2000-11-24 Anvendelse av paratyroidhormon for fremstilling av et preparat for a redusere benfraktur
NO20072983A NO20072983L (no) 1998-08-19 2007-06-11 Anvendelse av paratyroidhormon for fremstilling av et medikament for a redusere risiko for frakturer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20005947A NO323984B1 (no) 1998-08-19 2000-11-24 Anvendelse av paratyroidhormon for fremstilling av et preparat for a redusere benfraktur

Country Status (33)

Country Link
US (2) US6977077B1 (no)
EP (3) EP2266598B1 (no)
JP (5) JP2002523375A (no)
KR (1) KR100454207B1 (no)
CN (1) CN1205997C (no)
AR (1) AR033639A1 (no)
AT (1) ATE231000T1 (no)
AU (1) AU746277B2 (no)
BR (1) BR9909445A (no)
CA (1) CA2325371C (no)
CO (1) CO5130020A1 (no)
CY (2) CY1113343T1 (no)
CZ (1) CZ301017B6 (no)
DE (2) DE15152726T1 (no)
DK (4) DK2907522T3 (no)
DZ (1) DZ2873A1 (no)
EA (1) EA003362B1 (no)
ES (4) ES2393200T3 (no)
HK (3) HK1030545A1 (no)
HR (1) HRP20000755A2 (no)
HU (2) HU230697B1 (no)
ID (1) ID29039A (no)
IL (2) IL138829A0 (no)
MY (1) MY129227A (no)
NO (2) NO323984B1 (no)
NZ (1) NZ507056A (no)
PE (1) PE20001089A1 (no)
PL (1) PL201688B1 (no)
PT (4) PT1769804E (no)
TR (1) TR200003455T2 (no)
TW (1) TW576747B (no)
UA (1) UA72205C2 (no)
WO (1) WO2000010596A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
EP1222465A1 (en) * 1999-09-20 2002-07-17 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
EP1531855A4 (en) 2002-01-10 2009-07-22 Osteotrophin Llc TREATMENT OF BONE DISEASES WITH SKELETTAL ANABOLIKA
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
MXPA06003064A (es) * 2003-09-19 2006-05-31 Pfizer Prod Inc Composiciones farmaceuticas y metodos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y hormona paratiroide.
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
RU2006143544A (ru) * 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
BRPI0509788A (pt) 2004-05-13 2007-10-23 Alza Corp aparato e método para liberação transdérmica de agentes de hormÈnio paratireóides
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
EP1879608A4 (en) * 2005-05-11 2009-11-11 Unigene Lab Inc METHOD FOR STIMULATING BONE FORMATION AND PRESERVATION
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
JP2009515535A (ja) * 2005-11-10 2009-04-16 ボード オブ コントロール オブ ミシガン テクノロジカル ユニヴァーシティー クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
WO2008125655A1 (en) 2007-04-13 2008-10-23 Kuros Biosurgery Ag Polymeric tissue sealant
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US9457056B2 (en) * 2007-12-04 2016-10-04 Ben-Gurion University Of The Negev Research And Development Authority Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis
EP2227263A2 (en) 2007-12-28 2010-09-15 Kuros Biosurgery AG Pdgf fusion proteins incorporated into fibrin foams
KR20170089018A (ko) 2009-09-09 2017-08-02 아사히 가세이 파마 가부시키가이샤 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
WO2012123028A1 (en) 2011-03-16 2012-09-20 Kuros Biosurgery Ag Pharmaceutical formulation for use in spinal fusion
KR20150116467A (ko) 2011-06-07 2015-10-15 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN108601833B (zh) * 2016-02-01 2022-11-15 伊莱利利公司 甲状旁腺激素-抗rankl抗体融合化合物
US20190381341A1 (en) * 2017-02-01 2019-12-19 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
CN111447943A (zh) 2018-10-29 2020-07-24 旭化成制药株式会社 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法
EP4010360A1 (en) 2019-08-09 2022-06-15 Flagship Pioneering Innovations VI, LLC Modulators of parathyroid hormone receptor (pthr1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
EP0800405A4 (en) * 1994-12-19 1998-11-11 Beth Israel Hospital CONTINUOUS ADMINISTRATION OF LOW DOSES OF HORMONE PARATHYRO DIENNE OR ITS AGONIST
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
ATE238043T1 (de) * 1994-12-22 2003-05-15 Astrazeneca Ab Parathyroidhormon pth enthaltende therapeutische zubereitung zur inhalation
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
HU226866B1 (en) * 1997-09-09 2009-12-28 Hoffmann La Roche Fracture healing using pthrp analogs
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
DK1769804T3 (da) 2012-10-15
HK1212602A1 (zh) 2016-06-17
UA72205C2 (uk) 2005-02-15
US20050197294A1 (en) 2005-09-08
NO323984B1 (no) 2007-07-30
BR9909445A (pt) 2000-12-12
HU230697B1 (hu) 2017-09-28
DK2907522T3 (en) 2017-10-23
ID29039A (id) 2001-07-26
KR100454207B1 (ko) 2004-10-26
JP2017190332A (ja) 2017-10-19
PT1769804E (pt) 2012-11-13
AU746277B2 (en) 2002-04-18
JP2002523375A (ja) 2002-07-30
US7163684B2 (en) 2007-01-16
EA200001015A1 (ru) 2001-02-26
HUP0101594A3 (en) 2002-01-28
CA2325371C (en) 2004-08-17
PL201688B1 (pl) 2009-04-30
NO20005947L (no) 2000-11-24
DK2266598T3 (en) 2017-05-15
CZ301017B6 (cs) 2009-10-14
CY1113343T1 (el) 2016-06-22
DE69904918T2 (de) 2003-11-13
EP1059933B1 (en) 2003-01-15
JP2011021035A (ja) 2011-02-03
DE69904918D1 (de) 2003-02-20
EP2907522B1 (en) 2017-08-02
ATE231000T1 (de) 2003-02-15
TR200003455T2 (tr) 2001-06-21
CN1308545A (zh) 2001-08-15
DZ2873A1 (fr) 2003-12-15
HK1030545A1 (en) 2001-05-11
ES2190244T3 (es) 2003-07-16
NO20005947D0 (no) 2000-11-24
PT1059933E (pt) 2003-06-30
CZ20004134A3 (cs) 2001-08-15
PE20001089A1 (es) 2000-11-04
ES2549551T3 (es) 2017-11-27
DE15152726T1 (de) 2015-12-10
TW576747B (en) 2004-02-21
JP2015028065A (ja) 2015-02-12
WO2000010596A1 (en) 2000-03-02
HU1200430D0 (hu) 2001-11-28
AR033639A1 (es) 2004-01-07
JP2014139220A (ja) 2014-07-31
ES2549551T1 (es) 2015-10-29
EP1059933A1 (en) 2000-12-20
AU5575099A (en) 2000-03-14
CO5130020A1 (es) 2002-02-27
MY129227A (en) 2007-03-30
NZ507056A (en) 2003-10-31
IL138829A (en) 2011-01-31
EA003362B1 (ru) 2003-04-24
PT2907522T (pt) 2017-10-23
HRP20000755A2 (en) 2001-02-28
ES2621653T3 (es) 2017-07-04
PL343595A1 (en) 2001-08-27
JP6177718B2 (ja) 2017-08-09
KR20010072763A (ko) 2001-07-31
HUP0101594A2 (hu) 2001-11-28
CN1205997C (zh) 2005-06-15
HK1102496A1 (en) 2007-11-23
IL138829A0 (en) 2001-10-31
ES2393200T3 (es) 2012-12-19
CA2325371A1 (en) 2000-03-02
PT2266598T (pt) 2017-05-02
EP2266598B1 (en) 2017-02-22
CY1119552T1 (el) 2018-03-07
DK2907522T1 (da) 2015-10-19
EP2266598A1 (en) 2010-12-29
EP2907522A1 (en) 2015-08-19
US6977077B1 (en) 2005-12-20
DK1059933T3 (da) 2003-04-07

Similar Documents

Publication Publication Date Title
NO20072983L (no) Anvendelse av paratyroidhormon for fremstilling av et medikament for a redusere risiko for frakturer
Bhandari et al. Management of acute hip fracture
Schildhauer et al. Triangular osteosynthesis of vertically unstable sacrum fractures: a new concept allowing early weight-bearing
Lorich et al. Osteoporotic pertrochanteric hip fractures: management and current controversies
Laohapoonrungsee et al. Two-hole side-plate DHS in the treatment of intertrochanteric fracture: results and complications
Mattsson et al. Resorbable cement for the augmentation of internally-fixed unstable trochanteric fractures: a prospective, randomised multicentre study
Denard Jr et al. Outcome of nonoperative vs operative treatment of humeral shaft fractures: a retrospective study of 213 patients
Kaplan et al. Surgical management of hip fractures: an evidence-based review of the literature. II: intertrochanteric fractures
Yuan et al. Osteoporotic spinal deformity: a biomechanical rationale for the clinical consequences and treatment of vertebral body compression fractures
Shore et al. Management of moderate to severe hip displacement in nonambulatory children with cerebral palsy
Paspati et al. Hip fracture epidemiology in Greece during 1977–1992
Grant et al. Internal fixation of osteoporotic bone
Rozell et al. Recent advances in the treatment of hip fractures in the elderly
Suckel et al. Evaluation of complications of three different types of proximal extra-articular femur fractures: differences in complications, age, sex and surviving rates
Sahota et al. Vertebral Fragility Fractures (VFF)—Who, when and how to operate
DeRogatis et al. Management of subtrochanteric femoral fracture nonunions
Sniger et al. Alendronate increases bone density in chronic spinal cord injury: a case report
McDowell et al. Evolution of sagittal imbalance following corrective surgery for sagittal plane deformity
Passias et al. Three-column osteotomy in adult spinal deformity: an analysis of temporal trends in usage and outcomes
Magu et al. Modified Pauwels' intertrochanteric osteotomy in neglected femoral neck fractures in children: a report of 10 cases followed for a minimum of 5 years
Seybold et al. Combining of small fragment screws and large fragment plates for open reduction and internal fixation of periprosthetic humeral fractures
Parikh et al. Rate of bone mineral density testing and subsequent fracture-free interval after distal forearm fracture in the Medicare population
Khateeb et al. Comparative study between dynamic hip screw and plate with proximal femoral nailing in trochanteric fractures of femur
Neviaser et al. Is kyphoplasty the standard of care for compression fractures in the spine, especially in the elderly?
Carlo et al. Preoperative manual on-table-traction for the reduction of thoracolumbar burst fractures: A technical note

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application